Similar articles

• Lenacapavir (Sunlenca) for multidrug-resistant HIV.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 May 1;65(1675):68-70. doi: 10.58347/tml.2023.1675c. Med Lett Drugs Ther. 2023. PMID: 37155250 No abstract available.
• Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

  Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, McDonald C, Ruane P, Sanchez WE, Scribner A, Liu SY, VanderVeen LA, Dvory-Sobol H, Rhee MS, Baeten JM, Koenig E. Gupta SK, et al. Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0. Lancet HIV. 2023. PMID: 36566079 Clinical Trial.
• Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.

  Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Ogbuagu O, et al. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
• Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.

  Tuan J, Ogbuagu O. Tuan J, et al. Expert Rev Anti Infect Ther. 2023 Jun;21(6):565-570. doi: 10.1080/14787210.2023.2203913. Epub 2023 Apr 20. Expert Rev Anti Infect Ther. 2023. PMID: 37067160 Review.
• Lenacapavir: First Approval.

  Paik J. Paik J. Drugs. 2022 Sep;82(14):1499-1504. doi: 10.1007/s40265-022-01786-0. Drugs. 2022. PMID: 36272024 Free PMC article. Review.